Suggestions
Elena Nicod
Director at Dolon Ltd
Elena Nicod is a Director at Dolon Ltd, a consultancy specializing in strategic pricing and market access, particularly in the context of rare diseases. She has a strong academic background, holding a PhD and having contributed to various discussions and presentations regarding health technology assessment (HTA) and the use of real-world evidence in the healthcare sector.12
Prior to her current role, Nicod served as a Senior Consultant at Dolon Ltd and has experience working with notable institutions such as Università Bocconi and the London School of Economics.4 Her expertise is recognized within the European Expert Group on Orphan Drug Incentives, where she collaborates with a multidisciplinary team focused on improving outcomes for rare disease patients.1
On LinkedIn, she is noted to have over 500 connections, indicating an active professional network.3
Highlights
Yesterday, at HTAi, we discussed the Rare Disease Interest Group work on what makes Health Technology Assessment so difficult for rare diseases. In this work, we developed a conceptual framework to qualify and explain the inherent characteristics common in rare diseases and that create challenges in HTA. It is not only about rarity, but the combination of rarity in conditions that are heterogeneous, severe, complex (e.g. chronic, progressive, multi-systemic) and for which we don't have a lot of knowledge and expertise. It's all these things together that create challenges for HTA and need to be considered in light of the immense epidemiological differences and age groups across the 6,000+ rare diseases. My take aways from the discussion:
- There is almost always going to be uncertainty in rare diseases - value frameworks need to allow for decisions to rely on value judgments and account for the extent to which this uncertainty is acceptable;
- Evidence feasibility needs to be considered in light of the population affected and the age of disease onset - clinical development programmes in a condition with childhood onset are completely different from those affecting both adults and children;
- While each rare disease is unique, there are aspects across rare diseases that are common, e.g. caregiver impact across paediatric neuromuscular conditions - collaboration across diseases is needed ;
- The high unmet needs and/or paediatric nature of these conditions will lead to a number of ethical challenges throughout development that need to be accounted for within the context of the decision being made. My personal conclusion - We need to revisit the question about rarity deserving special status by broadening the definition of rarity to reflect the combination of characteristics that make these conditions so difficult to live with! Feedback welcomed! #HTAi2024Sevilla #rarediseases #HTA #orphandrugs A big thank you to my co-panellists: Sheela Upadhyaya Mark Sheehan Fleur Chandler and Prof. Antonio Gonzalez-Meneses
Posting this on behalf of EUpALS: This is a great opportunity to work for an incredibly active umbrella EU patient organisation. Please share with your contacts that might be interested!
